Are nodal metastases in ovarian cancer chen1oresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy

Background: To report the rates of nodal involvement in epithelial ovarian cancer (EOC) in patients who underwent initial lymphadenectomy (before chemotherapy) and patients who underwent lymphadenectomy after chemotherapy.

Study design: The rates of nodal involvement in 205 patients with EOC who underwent complete bilateral pelvic and para-aortic lympadenectomy between 1985 and 2001 were analyzed: 100 women underwent this surgical procedure before chemotherapy (initial surgery) and 105 at the end of chemotherapy (second-look surgery for 77 patients with 6 courses of a platinum-based regimen) or during chemotherapy (interval debulking surgery for 28 patients with 3 courses of a platinum-based regimen containing paclitaxel).

Results: The overall frequency of lymph-node involvement was 35% (35/100) in patients treated with initial surgery, 54% (15/28) in the interval debulking surgery group and 36% (28/77) in the second-look surgery group. In patients with Stage III disease, the rates of nodal involvement in patients treated with initial surgery, interval debulking surgery (with paclitaxel-based regimen) and second-look surgery were respectively: 53% (15/28), 58% (15/26) and 48% (20/42). The rates of nodal involvement in patients who underwent lymphadenectomy prior to or after chemotherapy were not statistically different whatever the stage of the disease. Adding paclitaxel to the platinum-based regimen does not seem to improve node sterilization rates.

Conclusions: The rates of nodal involvement seem to be similar in patients treated before or after chemotherapy. Such results suggest that nodal metastases are not as chemosensitive as peritoneal lesions. However, further studies are needed to evaluate the therapeutic value of lymphadenectomy in patients with nodal involvement.

Ovarian cancer; Chemotherapy; Nodal involvement; Para-aortic lymphadenectomy; Chemoresistance

[1] Griffiths T.C., Parker L.M., Fuller A.F.: "Role of cytoreducllve surgical treatment in the managem ent of advanced o varian cancer". Cancer Treat. Rep., 1979, 63, 235.

[2] Michel G., De Iaco P., Castaigne D., El-Hassan M.J., Lobreglio R., Lhomme C. et al.: "Extensive cytoreductive surgery in advanced ovarian carcinoma". Eur. 1. Gynaec. Oncol., 1997, 18, 9.

[3] Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., Elashoff R.M.: "Primary cytoreductive surgery for epithelial ovarian cancer". Obstet. Gynecol., 1983, 61, 413.

[4] Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M. et al.: "The effect of the diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma". Am. J. Obstet. Gynecol., 1994, 170, 974.

[5] De Poncheville L., Perrotin F., Lefrancq T., Lansac J., Body G.: "Does paraaortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently confined to the ovaries?". Eur. J. Cancer, 2001, 37, 210.

[6] Michel G., Morice P., Castaigne D., Leblanc M., Rey A., Duvillard P.: "Lymphatic spread of stage IB/II cervical carcinoma: Anatomy and surgical implications". Obstet. Gynecol., 1998, 91, 360.

[7] Morice P.,J oulie F.,C amatte S.,A tallah D.,R ouzier R.,P autier P. et al.: "Lymph node involvement in epithelial ovarian cancer: Analysis of 276 pelvic and para-aortic lymphadenectomies and surgical implications". J. Am. Coll. Surg., 2003, 197, 198.

[8] Morice P., Brehier-Ollive D., Rey A., Lhomme C., Pautier P., Duvillard P. et al.: "Results of interval de bulking surgery in advanced stage ovarian cancer: An exposed-nonexposed study". Ann. Oneal., 2003, 14, 74.

[9] Burghardt E., Winter R.: "The effect of chemotherapy on lymph node metastases in ovarian cancer". Baillie res Clin. Obst et. Gynaecol.,1 989, 3, 167.

[10] Wu P.C., Qu J.Y., Lang J.H., Tang M.Y., Lian L.J.: "Lymph node metastasis of ovarian cancer: a preliminary survey of 74 cases of lymphadenectomy". Am. J. Obstet. Gynecol., 1986, 155, 1103.

[11] Wu P.C., Lang J.H., Huang R.L., Qu J.Y., Wang H., Tang M.Y. et al.: "Lymph node metastasis and retroperitoneal lymphadenectomy in ovarian cancer". Baillieres Clin. Obstet. Gynaecol., 1989, 3, 143.

[12] Di Re F., Fontanelli R., Raspagliesi F., Di Re E.: "Pelvic and paraaortic lymphadenectomy in cancer of the ovary". Baillieres Clin. Obstet. Gynaecol., 1989, 3, 131.

[13] Scarabelli C., Gallo A., Zarrelli A., Visentin C., Campagnutta E.: "Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival". Gynecol. Oncol., 1995, 56, 328.

[14] Baiocchi G., Grosso G., Di Re E., Fontanelli R., Raspagliesi F., Di Re F.: "Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer". Gynecol. Oneal., 1998, 69, 151.

[15] Zinzindohoue C., Lujan R., Boulet S., Spirito C., Bobin J.Y.: "Pelvic and para-aortic lymphadenectomy in epithelial ovarian cancer. Report of a series of 86 cases". Ann. Chir., 2000, 125, 163.

[16] Kimball R.E., Schlaerth J.B., Kute T.E., Schlaerth A.C., Santoso J., Ballon S.C. et al.: "Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: clinical and biologic significance". Am. J. Obstet. Gynecol., 1997, 176, 1319.

[17] Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E. et al.: "Randomized intergroup trial of cisplatinpaclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results". J. Natl. Cancer Inst., 2000, 92, 699.

[18] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y. et al.: "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer". N. Engl. J. Med., 1996, 334, I.

[19] Spirtos N.M.,G ross G.M.,F reddo J.L.,B allon S.C.: "Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy". Gynecol. Oneal., 1995, 56, 345.

[20] Di Re F., Baiocchi G., Fontanelli R., Grosso G., Cobellis L., Raspagliesi F. et al.: "Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases". Gynecol. Oneal., 1996, 62, 360.

[21] Trimbos J.B., Vergote I., Bolis G., Vermorken J.B., Mangioni C., Madronal C. et al.: "Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial". J. Natl. Cancer Inst., 2003, 95, 113.

[22] Onda T., Yoshikawa H., Yasugi T., Mishima M., Nakagawa S., Yamada M. et al.: "Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to Stage I/II patients and superior survival to other stage III patients". Cancer, 1998, 83, 1555.

[23] Ho C.M., Chien T.Y., Shih B.Y., Huang S.H.: "Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma". Gynecol. Oneal., 2003, 88, 394.